Join
Live feed
·
PRReleasevia Quantisnow
BridgeBio Pharma Inc. logo

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

ByQuantisnow·Wall Street's wire, on your screen.
BBIO· BridgeBio Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBIO (BridgeBio Pharma Inc.) and more on Quantisnow.